CONFIDENCE IN THE CLASSROOM


Team up with VALTOCO® (diazepam nasal spray)
to change the seizure rescue experience at school

Wed, May 8 • 1:00 PM - 2:00 PM ET
Presented by:
Dr. Kate Labiner, MD
Thur, May 9 • 1:00 PM - 2:00 PM ET
Tues, May 21 • 1:00 PM - 2:00 PM ET
Presented by:
Dr. Kate Labiner, MD
Thur, May 23 • 2:00 PM - 3:00 PM ET

Presenters

Sandra Dewar, PhD, RN, FAES, FAAN, Neurology
Sandra Dewar PhD, RN, FAES, FAAN

Assistant Professor
Epilepsy Program Manager
Department of Neurology
Virginia Commonwealth University
Richmond, VA

Dr Dewar earned her doctorate from the UCLA School of Nursing, with a dissertation on “Perceptions of Illness Severity in Adults with Focal, Drug-Resistant Epilepsy.” She recently joined the faculty at Virginia Commonwealth University in Richmond, as an Assistant Professor of Neurology and the epilepsy program manager.

Dr Dewar holds fellowships of the American Epilepsy Society, and the American Academy of Nursing. Her extensive clinical experience and research activities have impacted practice standards across treatment settings and levels of specialization in the USA and globally. Her international influence includes her work as an executive team member of the Nursing Section of the International League Against Epilepsy.

She currently leads an active program of research. Her many published articles, abstracts, and book chapters are a clear demonstration of her commitment to overcoming treatment barriers in epilepsy, and her expertise in the field.

Labiner Katherine
Katherine “Kate” Labiner, MD

Pediatric Neurologist, Epileptologist, and
Sports Neurologist
Child Neurology Consultants of Austin
Austin, TX

Dr Labiner is a pediatric neurologist, an epileptologist, and sports neurologist. She earned her Bachelor of Science in neuroscience and behavioral biology from Emory University. While at Emory, she played lacrosse for 4 years and served as co-captain her senior year. She then graduated from the University of Arizona College of Medicine, followed by completion of a general pediatric residency at the University of Hawai’i.

Dr Labiner later moved to the University of Texas Southwestern for her pediatric neurology fellowship where she served as chief resident. She also fulfilled a fellowship in clinical neurophysiology and sports neurology and conducted research on complex febrile seizures and new-onset refractory status epilepticus in pediatrics.

Dr Labiner is passionate about working with young athletes and supporting their neurological needs as they age and transition between adolescence and adulthood. She provides sports neurology and concussion health guidance for many local high schools and college athletic programs. She is fluent in Spanish and has served as a healthcare provider both in the United States and Mexico. She is also an active member of the American Epilepsy Society.

In her spare time, Dr Labiner enjoys playing and cheering on a variety of sports, particularly her favorite Arizona Wildcats. She also loves spending time outdoors—especially near the water— with her beloved dog.

Confidence in the Classroom

Team up with VALTOCO® (diazepam nasal spray) to change the seizure rescue experience at school
Indication

VALTOCO® (diazepam nasal spray) is indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (ie, seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in patients with epilepsy 6 years of age and older.

IMPORTANT SAFETY INFORMATION

WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS

  • Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation.
  • The use of benzodiazepines, including VALTOCO, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes. Before prescribing VALTOCO and throughout treatment, assess each patient’s risk for abuse, misuse, and addiction.
  • The continued use of benzodiazepines may lead to clinically significant physical dependence. The risks of dependence and withdrawal increase with longer treatment duration and higher daily dose. Although VALTOCO is indicated only for intermittent use, if used more frequently than recommended, abrupt discontinuation or rapid dosage reduction of VALTOCO may precipitate acute withdrawal reactions, which can be life-threatening. For patients using VALTOCO more frequently than recommended, to reduce the risk of withdrawal reactions, use a gradual taper to discontinue VALTOCO.

Contraindications: VALTOCO is contraindicated in patients with:

  • Hypersensitivity to diazepam
  • Acute narrow-angle glaucoma

Central Nervous System (CNS) Depression

Benzodiazepines, including VALTOCO, may produce CNS depression. Caution patients against engaging in hazardous activities requiring mental alertness, such as operating machinery, driving a motor vehicle, or riding a bicycle, until the effects of the drug, such as drowsiness, have subsided, and as their medical condition permits.

The potential for a synergistic CNS-depressant effect when VALTOCO is used with alcohol or other CNS depressants must be considered, and appropriate recommendations made to the patient and/or care partner.

Suicidal Behavior and Ideation

Antiepileptic drugs (AEDs), including VALTOCO, increase the risk of suicidal ideation and behavior. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or unusual changes in mood or behavior.

Glaucoma

Benzodiazepines, including VALTOCO, can increase intraocular pressure in patients with glaucoma. VALTOCO may be used in patients with open-angle glaucoma only if they are receiving appropriate therapy. VALTOCO is contraindicated in patients with narrow-angle glaucoma.

Neonatal Sedation and Withdrawal Syndrome

Use of VALTOCO late in pregnancy can result in sedation (respiratory depression, lethargy, hypotonia) and/or withdrawal symptoms (hyperreflexia, irritability, restlessness, tremors, inconsolable crying, and feeding difficulties) in the neonate. Monitor neonates exposed to VALTOCO during pregnancy or labor for signs of sedation and monitor neonates exposed to VALTOCO during pregnancy for signs of withdrawal; manage these neonates accordingly.

Risk of Serious Adverse Reactions in Infants due to Benzyl Alcohol Preservative

VALTOCO is not approved for use in neonates or infants. Serious and fatal adverse reactions, including “gasping syndrome,” can occur in neonates and low-birth-weight infants treated with benzyl alcohol–preserved drugs, including VALTOCO. The “gasping syndrome” is characterized by central nervous system depression, metabolic acidosis, and gasping respirations. The minimum amount of benzyl alcohol at which serious adverse reactions may occur is not known.

Adverse Reactions

The most common adverse reactions (at least 4%) were somnolence, headache, and nasal discomfort.

Diazepam, the active ingredient in VALTOCO, is a Schedule IV controlled substance.

To report SUSPECTED ADVERSE REACTIONS, contact Neurelis, Inc. at 1-866-696-3873 or FDA at 1-800-FDA-1088 (www.fda.gov/medwatch).

Please read full Prescribing Information, including Boxed Warning, for additional important safety information.

© Neurelis, Inc. 2023. All rights reserved.
NEURELIS, VALTOCO, and the NEURELIS and VALTOCO logos are trademarks or registered trademarks of Neurelis, Inc.
 US-PRC-21-00293-v4 04/2024